Drug Trial Radar · NCT01694849
Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)
Last checked: Nov 19, 2026Latest source record: Nov 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
275
Actual
Start
Sep 2012
Primary completion
Feb 2015
Study completion Dec 2015
Sponsor
- Lead sponsor
- GenfitIndustry
- Sponsor type
- Industry
- Collaborators
- Naturalpha; Premier Research
- First posted
- Sep 27, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Abdominal obesity and type-2 Diabetes are associated with chronic liver disorders resulting from the accumulation of fat in the liver (steatosis), which may progress towards hepatitis and possibly lead to cirrhosis and liver cancer. NAFLD (Non Alcoholic Fatty Liver Disease) is considered as the most common form of chronic liver disease in adults in the United States, Australia, Asia and Europe. In the USA, the estimated prevalence of NAFLD is 20-30% of the adult population. Non-alcoholic Steatohepatitis (NASH) is a progressing form of NAFLD, which corresponds to hepatic steatosis associated with inflammation and liver cell injury upon microscopic examination of a liver biopsy. This condition may lead to advanced fibrosis and cirrhosis and deserves serious medical management. Up to now, there is no effective drug which has clearly demonstrated therapeutic efficacy which may help lifestyle and dietary recommendations in the resolution of NASH. In this context, GENFIT is developing a new liver targeted drug candidate, GFT505, for the treatment of NASH and the reduction of multiple cardiometabolic risk factors associated with the metabolic syndrome and type 2 Diabetes. This phase IIb study will evaluate the efficacy and safety of GFT505 80mg and 120mg once daily for 52 weeks on the reversal of NASH without worsening of fibrosis, based on liver biopsy assessments.
Conditions
- Non-Alcoholic Steatohepatitis (NASH)
Interventions
GFT505 80mgDrug
GFT505 120mgDrug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Responders With Disappearance of Steatohepatitis Without Worsening of Fibrosis (ie, Participants no Longer Meeting the Criteria for Steatohepatitis)Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Locations
56 sites in 9 countries. Site status is shown where the registry gives one.
Site 920
Fresno, California
Site 903
La Jolla, California
Site 911
Aurora, Colorado
Site 912
Gainesville, Florida
Site 924
Atlanta, Georgia
Site 917
Atlanta, Georgia
Site 909
New Orleans, Louisiana
Site 921
Worcester, Massachusetts
Site 902
Detroit, Michigan
Site 927
New York, New York
Site 908
Durham, North Carolina
Site 919
Philadelphia, Pennsylvania
Site 916
Memphis, Tennessee
Site 913
Fort Sam Houston, Texas
Site 923
Houston, Texas
Site 906
San Antonio, Texas
Site 931
Salt Lake City, Utah
Site 930
Charlottesville, Virginia
Site 901
Richmond, Virginia
Site 205
Brussels, Belgium
Site 201
Edegem, Belgium
Site 204
Ghent, Belgium
Site 202
Haine-Saint-Paul, Belgium
Site 203
Leuven, Belgium
Site 106
Amiens, France
Site 102
Angers, France
Site 114
Clichy, France
Site 103
Lille, France
Site 113
Lyon, France
Site 111
Marseille, France
Site 108
Montpellier, France
Site 104
Nantes, France
Site 109
Nice, France
Site 112
Paris, France
Site 101
Paris, France
Site 107
Pessac, France
Site 405
Bonn, Germany
Site 404
Mainz, Germany
Site 507
Milan, Italy
Site 503
Palermo, Italy
Showing 40 of 56 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.